MORE►
Research Bridge Partners
GenrAb CEO Larry Tiffany, who is leading the company's push to bring a first-in-class neuroprotective therapy into the clinic, also serves as Executive Chairman and Director at Medcura. [Sources: Medcura photo; iStock background; DI Studio]
UT Southwestern Spinout Emerges From Stealth With $5.6M to Push ‘First in Class’ Neuroprotective Therapy Into the Clinic
by Quincy Preston | Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
by Lance Murray |
Mar 24, 2025
Jibe Therapeutics is developing a next-generation cancer treatment that helps the immune system better recognize and attack tumors. As a result of its "Golden Ticket" pitch competition win, Jibe is relocating its research operations to Dallas' Pegasus Park.
MORE►
by Lance Murray |
Oct 24, 2024
Oncology companies seeking seed-stage through Series A funding are invited to apply to the Golden Ticket Pitch Competition, which will be held on March 11, 2025.
MORE►
by Quincy Preston |
Aug 9, 2024
With a new CEO and three seasoned industry veterans joining its board, Research Bridge Partners is focused on moving university innovations from the lab to the marketplace.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
MORE►
